STOCK TITAN
  1. Home
  2. News
  3. B

Barnes Group Inc. - B STOCK NEWS

Welcome to our dedicated news page for Barnes Group (Ticker: B), a resource for investors and traders seeking the latest updates and insights on Barnes Group.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Barnes Group's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Barnes Group's position in the market.

News
Barnes Announces Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast
Rhea-AI Summary
Barnes Group Inc. (NYSE: B) will release its Q4 and full year 2023 financial results on February 16, 2024, before the market opens. A conference call to discuss the results and the Company’s outlook will also be hosted at 8:30 a.m. (ET) on that day. The public can access the conference through a live audio webcast on the Investor Relations section of the Barnes website. Supplemental materials will be posted prior to the call, and a recorded playback will be available until February 23, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
earnings
-
News
LEQEMBI® to be launched in Japan for Alzheimer's disease on December 20
Rhea-AI Summary
BioArctic AB's (Nasdaq Stockholm: BIOA B) partner Eisai announced the launch of LEQEMBI in Japan on December 20, following its inclusion in the price listing on the Japan National Health Insurance drug price list. The product obtained approval for the indication of slowing progression of mild cognitive impairment and mild dementia due to Alzheimer's disease in Japan on September 25, 2023. LEQEMBI selectively binds to soluble and insoluble amyloid-beta aggregates, reducing Aβ protofibrils and plaques in the brain. The launch in Japan makes it the second country to have the product on the market, following the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.24%
Tags
none
-
News
Hexagon and JSOL Corporation enter strategic partnership to accelerate EV powertrain design with virtual prototyping
Rhea-AI Summary
Hexagon's Manufacturing Intelligence division (HEX) has partnered with JSOL Corporation to accelerate virtual prototyping of electrified powertrains through multi-physics simulation. This strategic collaboration aims to address the rapid electrification of industries like automotive and aerospace transport, offering comprehensive simulation solutions for system design problems in the virtual world.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
partnership
News
Infor Complements its Industry Cloud Platform with Enterprise Quality Management and Environmental, Health & Safety Solutions from ETQ
Rhea-AI Summary
Infor® (INF) partners with ETQ to enhance quality management and environmental, health, and safety solutions for various industries. ETQ Reliance offers QMS and EHS applications, while Infor CloudSuite manages product and quality specifications, inspections, and track & trace capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.43%
Tags
none
-
News
Lecanemab winner in two categories at The Scrip Awards 2023
Rhea-AI Summary
BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) invention lecanemab (LEQEMBI®), partnered with Eisai, was awarded the Best New Drug and the award for the Clinical Advance of the Year at the Scrip Awards 2023. The awards celebrate the best innovations and achievements of the international biopharma industry. Lecanemab is recognized for its excellence in pharmaceutical development, being the first and only treatment approved in Japan and the United States shown to reduce the rate of disease progression and to slow cognitive and functional decline in Alzheimer's disease patients. The success of the Phase 3 Clarity AD study of lecanemab led to the award for Clinical Advance of the Year. BioArctic and Eisai are preparing for a joint commercialization of lecanemab in the Nordic region.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
none
-
News
Integrum plans to submit a PMA application to the FDA for the use of OPRA in transhumeral amputations based on existing clinical data
Rhea-AI Summary
Integrum (Nasdaq First North Growth Market: INTEG B) plans to submit a PMA application to the FDA for the use of OPRA in transhumeral amputations based on existing clinical data. The company aims to broaden the regulatory approval in the US for the OPRA Implant System.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
clinical trial
News
Correction missing MAR reference: Integrum publishes preliminary revenue, result and and cash flow figures for Q2, 2023
Rhea-AI Summary
INTEG B - Integrum (publ) Expects Higher Q2 Revenue, Operating Profit, and Cash Flow, Preliminary Figures Show 36.2% Revenue Increase and 611.1% Operating Profit Surge
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.63%
Tags
none
-
News
Clinical study of Integrum's OPRA™ Implant System on below-knee amputations will include up to 30 patients and is fully funded by the Department of Defense
Rhea-AI Summary
Integrum (NASDAQ First North Growth Market: INTEG B) announces full funding from the US Department of Defense for a clinical study of OPRA™ Implant System on up to 30 patients with transtibial amputations. The study will be conducted at the Walter Reed National Military Medical Center. The FDA-approved study will provide crucial data for future regulatory processes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.63%
Tags
clinical trial
-
News
New Study: Project Management Information Systems Further Benefit Capital Building Programs When Applied to Multiple Processes
Rhea-AI Summary
Dodge Construction Network and Projectmates reveal that 61% of owners using PMIS for most of their capital management activities experience improved cost predictability. The report emphasizes the benefits of expanding the use of PMIS, including better informed decisions (74% vs 39%), improved design solutions (67% vs 31%), and the ability to mitigate design and construction risks (51% vs 30%). Strategic approach to PMIS is crucial for success, with centralized expertise yielding the strongest results in document and schedule management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.72%
Tags
none
News
Integrum publishes preliminary revenue, result and and cash flow figures for Q2, 2023
Rhea-AI Summary
Integrum (NASDAQ First North Growth Market: INTEG B) expects Q2 revenue, operating profit, and cash flow to exceed market expectations. Revenue expected at 27.5 MSEK, a 36.2% increase from last year. Operating profit expected at 6.4 MSEK, with an increase attributed to activity and improved cost structure. Cash flow expected at 3.4 MSEK. Complete results to be presented in the quarterly report for August - October 2023 on December 4, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.72%
Tags
none
Stock B logo
Barnes Group Inc.

NYSE:B

B Rankings

#1936 Ranked by Market Cap
#4450 Ranked by Stock Gains
#1498 Ranked by Dividends

B Stock Data

1.72B
45.58M
9.12%
92.61%
2.06%
Aircraft Engine and Engine Parts Manufacturing
Manufacturing
Link
US
Bristol

About B

barnes group inc. is an international industrial and aerospace manufacturer and service provider, serving a wide range of end markets and customers. the highly engineered products, differentiated industrial technologies, and innovative solutions delivered by barnes group are used in far-reaching applications that provide transportation, manufacturing, healthcare products, and technology to the world. with approximately 4,700 dedicated employees, at more than 60 locations worldwide, on four continents across the globe, barnes group continues to build on our long-standing tradition of excellence in precision manufacturing and logistics solutions, while at the same time, investing in leading-edge technologies and applying our expertise in newer break-through markets. barnes group operates under two global business segments - industrial and aerospace. at barnes group, there are no limits to your career path - only opportunities for success! explore your future and career potential at